Gemcitabine in locally advanced and/or m
β
Hans von der Maase
π
Article
π
2000
π
Elsevier Science
π
English
β 90 KB
Gemcitabine is a promising new drug in patients with locally advanced and/or metastatic transitional cell carcinoma of the urothelium. The drug has been tested as a single-agent in one phase I study and four phase II studies. Gemcitabine was administered on days 1, 8 and 15 every 28 days with a dose